BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29214525)

  • 1. Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors.
    Ciołczyk-Wierzbicka D; Gil D; Laidler P
    Med Oncol; 2017 Dec; 35(1):7. PubMed ID: 29214525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
    Lasithiotakis KG; Sinnberg TW; Schittek B; Flaherty KT; Kulms D; Maczey E; Garbe C; Meier FE
    J Invest Dermatol; 2008 Aug; 128(8):2013-23. PubMed ID: 18323781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of cell proliferation using silencing of N-cadherin gene by siRNA process in human melanoma cell lines.
    Ciołczyk-Wierzbicka D; Gil D; Laidler P
    Curr Med Chem; 2012; 19(1):145-51. PubMed ID: 22300088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lewis y regulate cell cycle related factors in ovarian carcinoma cell RMG-I in vitro via ERK and Akt signaling pathways.
    Liu D; Liu J; Lin B; Liu S; Hou R; Hao Y; Liu Q; Zhang S; Iwamori M
    Int J Mol Sci; 2012; 13(1):828-839. PubMed ID: 22312289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.
    Mirza AM; Gysin S; Malek N; Nakayama K; Roberts JM; McMahon M
    Mol Cell Biol; 2004 Dec; 24(24):10868-81. PubMed ID: 15572689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor I induces proliferation and migration of porcine trophectoderm cells through multiple cell signaling pathways, including protooncogenic protein kinase 1 and mitogen-activated protein kinase.
    Jeong W; Song G; Bazer FW; Kim J
    Mol Cell Endocrinol; 2014 Mar; 384(1-2):175-84. PubMed ID: 24508636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK drives cyclin D1 hyperelevation during geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest.
    Datta NS; Chen C; Berry JE; McCauley LK
    J Bone Miner Res; 2005 Jun; 20(6):1051-64. PubMed ID: 15883646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
    Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
    Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synergistic effect of targeted inhibition of MEK/ERK and PI3K/AKT survival signaling pathways on induction of apoptosis in melanoma].
    Wang XY; Cheng Y; Du JP; Chen DG; Yang XS; Yang ZM; Huang N
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):355-61. PubMed ID: 24941796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of ERK1/2, p38 MAPK, and PI3K/Akt signaling pathways in the regulation of cell cycle progression by PTHrP in colon adenocarcinoma cells.
    Calvo N; Martín MJ; de Boland AR; Gentili C
    Biochem Cell Biol; 2014 Aug; 92(4):305-15. PubMed ID: 25051885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
    McDonald GT; Sullivan R; Paré GC; Graham CH
    Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitor everolimus reduces invasiveness of melanoma cells.
    Ciołczyk-Wierzbicka D; Gil D; Zarzycka M; Laidler P
    Hum Cell; 2020 Jan; 33(1):88-97. PubMed ID: 31586300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.